Novo Nordisk's ZEUS trial failed to show MACE reduction, and hsCRP reduction data were not disclosed, fueling questions about hsCRP as a surrogate for cardiovascular risk. BioAge's BGE-102 NLRP3 program remains high-risk, with key readouts in 2026 and ophthalmology data expected in 2027. The stock has fallen as investors reassess NLRP3 exposure and near-term catalysts.
BioAge Labs Inc. announced positive Phase 1 data for its oral NLRP3 inhibitor BGE-102, causing shares to rise. The results show over 85% reduction in hs-CRP levels, indicating strong efficacy, with further trials set for mid-2026 expected to bolster growth prospects.
